Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor

Oct 15, 2019

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2019 Financial Results

Oct 15, 2019

Posted by PTC Therapeutics, Inc.

Seattle Children’s Building Cure Opens in Downtown Seattle to Accelerate Pediatric Research Discoveries

Oct 15, 2019

ABX 2019 – Converting Suburban Office Buildings Into Laboratory Facilities

Oct 08, 2019

Posted by ABI-LAB

Asymmetrex Obtains UK Patent for Tissue Stem Cell-Specific Counting and Testing

Oct 08, 2019

PTC Therapeutics Establishes Strategic Collaboration with Aldevron to Support GMP Plasmid Manufacturing

Oct 07, 2019

Posted by PTC Therapeutics, Inc.

PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna™ (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy

Oct 04, 2019

Posted by PTC Therapeutics, Inc.

Akero Therapeutics and InSphero partner to evaluate AKR-001 using InSphero’s 3D InSight™ Human Liver Disease platform

Oct 03, 2019

Asymmetrex Leads OCTNE 2019 Discussion of the Growing Need for Tissue Stem Cell-Specific Dosing In Stem Cell Clinical Trials

Oct 03, 2019